MedTrace Logo

Treatment of Schizophrenic Patients With Ziprasidone

NCT00579670 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2021-03-10

Study results available
· View outcomes & findings →

Summary

To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.

Conditions

Interventions

DRUG

Ziprasidone

Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00579670 on ClinicalTrials.gov